Yongping Yue
Overview
Explore the profile of Yongping Yue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
3059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hakim C, Wasala N, Nelson C, Wasala L, Yue Y, Louderman J, et al.
JCI Insight
. 2018 Dec;
3(23).
PMID: 30518686
Adeno-associated virus-mediated (AAV-mediated) CRISPR editing is a revolutionary approach for treating inherited diseases. Sustained, often life-long mutation correction is required for treating these diseases. Unfortunately, this has never been demonstrated...
22.
Patel A, Zhao J, Yue Y, Zhang K, Duan D, Lai Y
Skelet Muscle
. 2018 Nov;
8(1):36.
PMID: 30466494
Background: Loss of sarcolemmal nNOSμ is a common manifestation in a wide variety of muscle diseases and contributes to the dysregulation of multiple muscle activities. Given the critical role sarcolemmal...
23.
Wasala N, Shin J, Lai Y, Yue Y, Montanaro F, Duan D
Hum Gene Ther
. 2018 Feb;
29(7):737-748.
PMID: 29433343
Heart disease is a major health threat for Duchenne/Becker muscular dystrophy patients and carriers. Expression of a 6-8 kb mini-dystrophin gene in the heart holds promise to change the disease...
24.
Hakim C, Wasala N, Pan X, Kodippili K, Yue Y, Zhang K, et al.
Mol Ther Methods Clin Dev
. 2017 Sep;
6:216-230.
PMID: 28932757
Micro-dystrophins are highly promising candidates for treating Duchenne muscular dystrophy, a lethal muscle disease caused by dystrophin deficiency. Here, we report robust disease rescue in the severe DBA/2J-mdx model with...
25.
Kodippili K, Hakim C, Pan X, Yang H, Yue Y, Zhang Y, et al.
Hum Gene Ther
. 2017 Aug;
29(3):299-311.
PMID: 28793798
Dual adeno-associated virus (AAV) technology was developed in 2000 to double the packaging capacity of the AAV vector. The proof of principle has been demonstrated in various mouse models. Yet,...
26.
Ghosh A, Yue Y, Long C, Bostick B, Duan D
Mol Ther
. 2017 Feb;
15(6):1220.
PMID: 28182924
No abstract available.
27.
Wasala N, Yue Y, Vance J, Duan D
J Mol Cell Cardiol
. 2016 Dec;
102:45-52.
PMID: 27908661
Dystrophin deficiency results in Duchenne cardiomyopathy, a primary cause of death in Duchenne muscular dystrophy (DMD). Gene therapy has shown great promise in ameliorating the cardiac phenotype in mouse models...
28.
Yue Y, Wasala N, Bostick B, Duan D
Mol Ther Methods Clin Dev
. 2016 Jul;
3:16045.
PMID: 27419194
Dystrophin gene replacement holds the promise of treating Duchenne muscular dystrophy. Supraphysiological expression is a concern for all gene therapy studies. In the case of Duchenne muscular dystrophy, Chamberlain and...
29.
Zhao J, Kodippili K, Yue Y, Hakim C, Wasala L, Pan X, et al.
Hum Mol Genet
. 2016 Jul;
25(17):3647-3653.
PMID: 27378693
Dystrophin is a large sub-sarcolemmal protein. Its absence leads to Duchenne muscular dystrophy (DMD). Binding to the sarcolemma is essential for dystrophin to protect muscle from contraction-induced injury. It has...
30.
Yue Y, Binalsheikh I, Leach S, Domeier T, Duan D
Expert Opin Orphan Drugs
. 2016 Jun;
4(2):169-183.
PMID: 27340611
Introduction: Cardiac involvement is a common feature in muscular dystrophies. It presents as heart failure and/or arrhythmia. Traditionally, dystrophic cardiomyopathy is treated with symptom-relieving medications. Identification of disease-causing genes and...